New clinical evidence highlights the potential of three-month synbiotic supplementation in attenuating post-exercise malaise and increasing brain metabolites in adults with post-COVID-19 chronic fatigue syndrome (CFS). A new randomized, placebo-controlled clinical trial published in the European Journal of Nutritioni has shown that daily supplementation with a synbiotic blend may help to manage key clinical features of post-COVID-19 chronic fatigue syndrome (CFS), such as exercise tolerance … [Read more...] about Synbiotics emerge as a promising tool for managing extreme fatigue and post-exercise malaise, clinical trial suggests
dsm-firmenich
From cellular aging to gut microbiome: dsm-firmenich highlights solutions to advance nutrition at Vitafoods 2025
dsm-firmenich, a leading innovator in health, nutrition, and beauty, is set to showcase solutions that advance nutrition at Vitafoods Europe 2025 on booth 3G58 with a display of its latest innovations in healthy longevity, gut health, and more. Healthy Longevity platform launch: Solutions, expertise, and innovation Vitafoods Europe 2025 will showcase dsm-firmenich's innovative Healthy Longevity platform, a comprehensive offering of nutritional solutions, scientific expertise, and … [Read more...] about From cellular aging to gut microbiome: dsm-firmenich highlights solutions to advance nutrition at Vitafoods 2025
Boost for infant health: India approves dsm-firmenich’s 2′-FL HMO
dsm-firmenich, a global innovator in health, nutrition, and beauty, has announced the approval of its human milk oligosaccharide (HMO), 2'-O-Fucosyllactose (2'-FL)—commercially known as GLYCARE® 2FL—as a functional ingredient for early life nutrition in India. This regulatory milestone marks a new opportunity to enhance infant health, as well as support HMO innovation in the region, with GLYCARE® 2FL representing dsm-firmenich’s first HMO approval in India. The Food Safety and Standards … [Read more...] about Boost for infant health: India approves dsm-firmenich’s 2′-FL HMO
